| 7-Nitroindazole | The risk or severity of adverse effects can be increased when Prazepam is combined with 7-Nitroindazole. | Experimental |
| Acepromazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Acepromazine. | Approved, Vet Approved |
| Aceprometazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Aceprometazine. | Approved |
| Adipiplon | The risk or severity of adverse effects can be increased when Prazepam is combined with adipiplon. | Investigational |
| Agomelatine | The risk or severity of adverse effects can be increased when Prazepam is combined with Agomelatine. | Approved, Investigational |
| Alfaxalone | The risk or severity of adverse effects can be increased when Prazepam is combined with Alfaxalone. | Vet Approved |
| Alfentanil | The risk or severity of adverse effects can be increased when Alfentanil is combined with Prazepam. | Approved, Illicit |
| Allopregnanolone | The risk or severity of adverse effects can be increased when Prazepam is combined with Sage 547. | Investigational |
| Alphacetylmethadol | The risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Prazepam. | Experimental, Illicit |
| Alprazolam | The risk or severity of adverse effects can be increased when Alprazolam is combined with Prazepam. | Approved, Illicit, Investigational |
| Ambroxol acefyllinate | The therapeutic efficacy of Prazepam can be decreased when used in combination with Ambroxol acefyllinate. | Experimental |
| Aminophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Aminophylline. | Approved |
| Amiodarone | The metabolism of Prazepam can be decreased when combined with Amiodarone. | Approved, Investigational |
| Amisulpride | The risk or severity of adverse effects can be increased when Prazepam is combined with Amisulpride. | Approved, Investigational |
| Amitriptyline | The risk or severity of adverse effects can be increased when Prazepam is combined with Amitriptyline. | Approved |
| Amobarbital | The risk or severity of adverse effects can be increased when Amobarbital is combined with Prazepam. | Approved, Illicit |
| Amoxapine | The risk or severity of adverse effects can be increased when Prazepam is combined with Amoxapine. | Approved |
| Amperozide | The risk or severity of adverse effects can be increased when Prazepam is combined with Amperozide. | Experimental |
| Aprepitant | The serum concentration of Prazepam can be increased when it is combined with Aprepitant. | Approved, Investigational |
| Aripiprazole | The risk or severity of adverse effects can be increased when Aripiprazole is combined with Prazepam. | Approved, Investigational |
| Articaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Articaine. | Approved |
| Asenapine | The risk or severity of adverse effects can be increased when Prazepam is combined with Asenapine. | Approved |
| Atazanavir | The metabolism of Prazepam can be decreased when combined with Atazanavir. | Approved, Investigational |
| Atomoxetine | The metabolism of Prazepam can be decreased when combined with Atomoxetine. | Approved |
| Azelastine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Azelastine. | Approved |
| Azelastine | The risk or severity of adverse effects can be increased when Prazepam is combined with Azelastine. | Approved |
| Baclofen | The risk or severity of adverse effects can be increased when Prazepam is combined with Baclofen. | Approved |
| Barbital | The risk or severity of adverse effects can be increased when Barbital is combined with Prazepam. | Illicit |
| Benperidol | The risk or severity of adverse effects can be increased when Prazepam is combined with Benperidol. | Investigational |
| Benzocaine | The risk or severity of adverse effects can be increased when Benzocaine is combined with Prazepam. | Approved |
| Benzyl alcohol | The risk or severity of adverse effects can be increased when Prazepam is combined with Benzyl alcohol. | Approved |
| Bexarotene | The serum concentration of Prazepam can be decreased when it is combined with Bexarotene. | Approved, Investigational |
| Boceprevir | The metabolism of Prazepam can be decreased when combined with Boceprevir. | Approved, Investigational |
| Bortezomib | The metabolism of Prazepam can be decreased when combined with Bortezomib. | Approved, Investigational |
| Bosentan | The serum concentration of Prazepam can be decreased when it is combined with Bosentan. | Approved, Investigational |
| Brexpiprazole | The risk or severity of adverse effects can be increased when Prazepam is combined with Brexpiprazole. | Approved |
| Brimonidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Brimonidine. | Approved |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved |
| Bromazepam | The risk or severity of adverse effects can be increased when Bromazepam is combined with Prazepam. | Approved, Illicit |
| Brompheniramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Brompheniramine. | Approved |
| Brotizolam | The risk or severity of adverse effects can be increased when Prazepam is combined with Brotizolam. | Approved, Withdrawn |
| Bupivacaine | The risk or severity of adverse effects can be increased when Bupivacaine is combined with Prazepam. | Approved, Investigational |
| Buprenorphine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. | Approved, Illicit, Investigational, Vet Approved |
| Buspirone | The risk or severity of adverse effects can be increased when Buspirone is combined with Prazepam. | Approved, Investigational |
| Butabarbital | The risk or severity of adverse effects can be increased when Butabarbital is combined with Prazepam. | Approved, Illicit |
| Butalbital | The risk or severity of adverse effects can be increased when Prazepam is combined with Butalbital. | Approved, Illicit |
| Butethal | The risk or severity of adverse effects can be increased when Butethal is combined with Prazepam. | Approved, Illicit |
| Butorphanol | The risk or severity of adverse effects can be increased when Butorphanol is combined with Prazepam. | Approved, Illicit, Vet Approved |
| Carbamazepine | The metabolism of Prazepam can be increased when combined with Carbamazepine. | Approved, Investigational |
| Carbinoxamine | The risk or severity of adverse effects can be increased when Prazepam is combined with Carbinoxamine. | Approved |
| Carfentanil | The risk or severity of adverse effects can be increased when Carfentanil is combined with Prazepam. | Illicit, Vet Approved |
| Carisoprodol | The risk or severity of adverse effects can be increased when Prazepam is combined with Carisoprodol. | Approved |
| Ceritinib | The serum concentration of Prazepam can be increased when it is combined with Ceritinib. | Approved |
| Cetirizine | The risk or severity of adverse effects can be increased when Prazepam is combined with Cetirizine. | Approved |
| Chloral hydrate | The risk or severity of adverse effects can be increased when Chloral hydrate is combined with Prazepam. | Approved, Illicit, Vet Approved |
| Chlordiazepoxide | The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Prazepam. | Approved, Illicit |
| Chlormezanone | The risk or severity of adverse effects can be increased when Chlormezanone is combined with Prazepam. | Approved, Withdrawn |
| Chloroprocaine | The risk or severity of adverse effects can be increased when Chloroprocaine is combined with Prazepam. | Approved |
| Chlorphenamine | The risk or severity of adverse effects can be increased when Prazepam is combined with Chlorphenamine. | Approved |
| Chlorpromazine | The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Prazepam. | Approved, Vet Approved |
| Chlorprothixene | The risk or severity of adverse effects can be increased when Chlorprothixene is combined with Prazepam. | Approved, Withdrawn |
| Chlorzoxazone | The risk or severity of adverse effects can be increased when Prazepam is combined with Chlorzoxazone. | Approved |
| Cinchocaine | The risk or severity of adverse effects can be increased when Cinchocaine is combined with Prazepam. | Approved, Vet Approved |
| Citalopram | The risk or severity of adverse effects can be increased when Prazepam is combined with Citalopram. | Approved |
| Clarithromycin | The metabolism of Prazepam can be decreased when combined with Clarithromycin. | Approved |
| Clemastine | The metabolism of Prazepam can be decreased when combined with Clemastine. | Approved |
| Clidinium | The risk or severity of adverse effects can be increased when Prazepam is combined with Clidinium. | Approved |
| Clobazam | The risk or severity of adverse effects can be increased when Prazepam is combined with Clobazam. | Approved, Illicit |
| Clomipramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Clomipramine. | Approved, Vet Approved |
| Clonazepam | The risk or severity of adverse effects can be increased when Prazepam is combined with Clonazepam. | Approved, Illicit |
| Clonidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Clonidine. | Approved |
| Clorazepate | The risk or severity of adverse effects can be increased when Clorazepate is combined with Prazepam. | Approved, Illicit |
| Clotrimazole | The metabolism of Prazepam can be decreased when combined with Clotrimazole. | Approved, Vet Approved |
| Clozapine | The risk or severity of adverse effects can be increased when Prazepam is combined with Clozapine. | Approved |
| Cobicistat | The metabolism of Prazepam can be decreased when combined with Cobicistat. | Approved |
| Cocaine | The risk or severity of adverse effects can be increased when Cocaine is combined with Prazepam. | Approved, Illicit |
| Codeine | The risk or severity of adverse effects can be increased when Codeine is combined with Prazepam. | Approved, Illicit |
| Conivaptan | The serum concentration of Prazepam can be increased when it is combined with Conivaptan. | Approved, Investigational |
| Crizotinib | The metabolism of Prazepam can be decreased when combined with Crizotinib. | Approved |
| Cyclizine | The risk or severity of adverse effects can be increased when Prazepam is combined with Cyclizine. | Approved |
| Cyclobenzaprine | The risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Prazepam. | Approved |
| Cyclosporine | The metabolism of Prazepam can be decreased when combined with Cyclosporine. | Approved, Investigational, Vet Approved |
| Cyproheptadine | The risk or severity of adverse effects can be increased when Prazepam is combined with Cyproheptadine. | Approved |
| Dabrafenib | The serum concentration of Prazepam can be decreased when it is combined with Dabrafenib. | Approved |
| Dantrolene | The risk or severity of adverse effects can be increased when Prazepam is combined with Dantrolene. | Approved |
| Dapiprazole | The risk or severity of adverse effects can be increased when Dapiprazole is combined with Prazepam. | Approved |
| Dapoxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Dapoxetine. | Investigational |
| Darunavir | The metabolism of Prazepam can be decreased when combined with Darunavir. | Approved |
| Dasatinib | The serum concentration of Prazepam can be increased when it is combined with Dasatinib. | Approved, Investigational |
| Deferasirox | The serum concentration of Prazepam can be decreased when it is combined with Deferasirox. | Approved, Investigational |
| Delavirdine | The metabolism of Prazepam can be decreased when combined with Delavirdine. | Approved |
| Deramciclane | The risk or severity of adverse effects can be increased when Prazepam is combined with deramciclane. | Investigational |
| Desflurane | The risk or severity of adverse effects can be increased when Desflurane is combined with Prazepam. | Approved |
| Desipramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Desipramine. | Approved |
| Desloratadine | The risk or severity of adverse effects can be increased when Prazepam is combined with Desloratadine. | Approved, Investigational |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when Prazepam is combined with Desvenlafaxine. | Approved |
| Dexamethasone | The serum concentration of Prazepam can be decreased when it is combined with Dexamethasone. | Approved, Investigational, Vet Approved |
| Dexbrompheniramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Dexbrompheniramine. | Approved |
| Dexmedetomidine | The risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Prazepam. | Approved, Vet Approved |
| Dextromoramide | The risk or severity of adverse effects can be increased when Dextromoramide is combined with Prazepam. | Experimental, Illicit |
| Dextropropoxyphene | The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Prazepam. | Approved, Illicit, Withdrawn |
| Dezocine | The risk or severity of adverse effects can be increased when Dezocine is combined with Prazepam. | Approved |
| Diazepam | The risk or severity of adverse effects can be increased when Diazepam is combined with Prazepam. | Approved, Illicit, Vet Approved |
| Difenoxin | The risk or severity of adverse effects can be increased when Prazepam is combined with Difenoxin. | Approved, Illicit |
| Dihydrocodeine | The risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Prazepam. | Approved, Illicit |
| Dihydroergotamine | The metabolism of Prazepam can be decreased when combined with Dihydroergotamine. | Approved |
| Dihydroetorphine | The risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Prazepam. | Experimental, Illicit |
| Dihydromorphine | The risk or severity of adverse effects can be increased when Dihydromorphine is combined with Prazepam. | Experimental, Illicit |
| Diltiazem | The metabolism of Prazepam can be decreased when combined with Diltiazem. | Approved |
| Dimenhydrinate | The risk or severity of adverse effects can be increased when Prazepam is combined with Dimenhydrinate. | Approved |
| Diphenhydramine | The risk or severity of adverse effects can be increased when Diphenhydramine is combined with Prazepam. | Approved |
| Diphenoxylate | The risk or severity of adverse effects can be increased when Diphenoxylate is combined with Prazepam. | Approved, Illicit |
| Doxepin | The risk or severity of adverse effects can be increased when Prazepam is combined with Doxepin. | Approved |
| Doxycycline | The metabolism of Prazepam can be decreased when combined with Doxycycline. | Approved, Investigational, Vet Approved |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Vet Approved |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Illicit |
| Dronedarone | The metabolism of Prazepam can be decreased when combined with Dronedarone. | Approved |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Vet Approved |
| Drotebanol | The risk or severity of adverse effects can be increased when Drotebanol is combined with Prazepam. | Experimental, Illicit |
| Duloxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Duloxetine. | Approved |
| Dyclonine | The risk or severity of adverse effects can be increased when Dyclonine is combined with Prazepam. | Approved |
| Dyphylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Dyphylline. | Approved |
| Ecgonine | The risk or severity of adverse effects can be increased when Ecgonine is combined with Prazepam. | Experimental, Illicit |
| Ecopipam | The risk or severity of adverse effects can be increased when Prazepam is combined with Ecopipam. | Investigational |
| Efavirenz | The serum concentration of Prazepam can be decreased when it is combined with Efavirenz. | Approved, Investigational |
| Eltanolone | The risk or severity of adverse effects can be increased when Prazepam is combined with Pregnanolone. | Investigational |
| Enflurane | The risk or severity of adverse effects can be increased when Enflurane is combined with Prazepam. | Approved, Vet Approved |
| Entacapone | The risk or severity of adverse effects can be increased when Prazepam is combined with Entacapone. | Approved, Investigational |
| Enzalutamide | The serum concentration of Prazepam can be decreased when it is combined with Enzalutamide. | Approved |
| Erythromycin | The metabolism of Prazepam can be decreased when combined with Erythromycin. | Approved, Vet Approved |
| Escitalopram | The risk or severity of adverse effects can be increased when Prazepam is combined with Escitalopram. | Approved, Investigational |
| Eslicarbazepine acetate | The serum concentration of Prazepam can be decreased when it is combined with Eslicarbazepine acetate. | Approved |
| Estazolam | The risk or severity of adverse effects can be increased when Estazolam is combined with Prazepam. | Approved, Illicit |
| Eszopiclone | The risk or severity of adverse effects can be increased when Eszopiclone is combined with Prazepam. | Approved |
| Ethanol | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Ethanol. | Approved |
| Ethchlorvynol | The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Prazepam. | Approved, Illicit, Withdrawn |
| Ethosuximide | The risk or severity of adverse effects can be increased when Prazepam is combined with Ethosuximide. | Approved |
| Ethotoin | The risk or severity of adverse effects can be increased when Prazepam is combined with Ethotoin. | Approved |
| Ethyl carbamate | The risk or severity of adverse effects can be increased when Prazepam is combined with Ethyl carbamate. | Withdrawn |
| Ethyl loflazepate | The risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Prazepam. | Approved, Illicit |
| Ethylmorphine | The risk or severity of adverse effects can be increased when Ethylmorphine is combined with Prazepam. | Approved, Illicit |
| Etidocaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Etidocaine. | Approved |
| Etifoxine | The risk or severity of adverse effects can be increased when Prazepam is combined with Etifoxine. | Withdrawn |
| Etizolam | The risk or severity of adverse effects can be increased when Prazepam is combined with Etizolam. | Approved |
| Etomidate | The risk or severity of adverse effects can be increased when Etomidate is combined with Prazepam. | Approved |
| Etoperidone | The risk or severity of adverse effects can be increased when Prazepam is combined with Etoperidone. | Approved |
| Etorphine | The risk or severity of adverse effects can be increased when Etorphine is combined with Prazepam. | Illicit, Vet Approved |
| Etravirine | The serum concentration of Prazepam can be decreased when it is combined with Etravirine. | Approved |
| Ezogabine | The risk or severity of adverse effects can be increased when Prazepam is combined with Ezogabine. | Approved |
| Felbamate | The risk or severity of adverse effects can be increased when Prazepam is combined with Felbamate. | Approved |
| Fencamfamine | The risk or severity of adverse effects can be increased when Fencamfamine is combined with Prazepam. | Approved, Illicit, Withdrawn |
| Fentanyl | The risk or severity of adverse effects can be increased when Fentanyl is combined with Prazepam. | Approved, Illicit, Investigational, Vet Approved |
| Fexofenadine | The risk or severity of adverse effects can be increased when Prazepam is combined with Fexofenadine. | Approved |
| Flibanserin | The risk or severity of adverse effects can be increased when Prazepam is combined with Flibanserin. | Approved |
| Fluconazole | The metabolism of Prazepam can be decreased when combined with Fluconazole. | Approved |
| Fludiazepam | The risk or severity of adverse effects can be increased when Fludiazepam is combined with Prazepam. | Approved, Illicit |
| Flunarizine | The risk or severity of adverse effects can be increased when Prazepam is combined with Flunarizine. | Approved |
| Flunitrazepam | The risk or severity of adverse effects can be increased when Flunitrazepam is combined with Prazepam. | Approved, Illicit |
| Fluoxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Fluoxetine. | Approved, Vet Approved |
| Flupentixol | The risk or severity of adverse effects can be increased when Flupentixol is combined with Prazepam. | Approved, Withdrawn |
| Fluphenazine | The risk or severity of adverse effects can be increased when Fluphenazine is combined with Prazepam. | Approved |
| Flurazepam | The risk or severity of adverse effects can be increased when Flurazepam is combined with Prazepam. | Approved, Illicit |
| Fluspirilene | The risk or severity of adverse effects can be increased when Prazepam is combined with Fluspirilene. | Approved |
| Fluticasone propionate | The risk or severity of adverse effects can be increased when Prazepam is combined with Fluticasone Propionate. | Approved |
| Fluvoxamine | The metabolism of Prazepam can be decreased when combined with Fluvoxamine. | Approved, Investigational |
| Fosamprenavir | The metabolism of Prazepam can be decreased when combined with Fosamprenavir. | Approved |
| Fosaprepitant | The serum concentration of Prazepam can be increased when it is combined with Fosaprepitant. | Approved |
| Fosphenytoin | The serum concentration of Fosphenytoin can be increased when it is combined with Prazepam. | Approved |
| Fospropofol | The risk or severity of adverse effects can be increased when Prazepam is combined with Fospropofol. | Approved, Illicit |
| Fusidic Acid | The serum concentration of Prazepam can be increased when it is combined with Fusidic Acid. | Approved |
| Gabapentin | The risk or severity of adverse effects can be increased when Gabapentin is combined with Prazepam. | Approved, Investigational |
| Gabapentin Enacarbil | The risk or severity of adverse effects can be increased when Prazepam is combined with gabapentin enacarbil. | Approved |
| Gamma Hydroxybutyric Acid | The risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Prazepam. | Approved, Illicit |
| Gepirone | The risk or severity of adverse effects can be increased when Prazepam is combined with Gepirone. | Investigational |
| Glutethimide | The risk or severity of adverse effects can be increased when Glutethimide is combined with Prazepam. | Approved, Illicit |
| Guanfacine | The risk or severity of adverse effects can be increased when Prazepam is combined with Guanfacine. | Approved, Investigational |
| Halazepam | The risk or severity of adverse effects can be increased when Halazepam is combined with Prazepam. | Approved, Illicit, Withdrawn |
| Haloperidol | The risk or severity of adverse effects can be increased when Haloperidol is combined with Prazepam. | Approved |
| Halothane | The risk or severity of adverse effects can be increased when Halothane is combined with Prazepam. | Approved, Vet Approved |
| Heroin | The risk or severity of adverse effects can be increased when Heroin is combined with Prazepam. | Approved, Illicit |
| Hexobarbital | The risk or severity of adverse effects can be increased when Hexobarbital is combined with Prazepam. | Approved |
| Hyaluronidase | The therapeutic efficacy of Prazepam can be decreased when used in combination with Hyaluronidase. | Approved, Investigational |
| Hydrocodone | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. | Approved, Illicit |
| Hydromorphone | The risk or severity of adverse effects can be increased when Hydromorphone is combined with Prazepam. | Approved, Illicit |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved |
| Idelalisib | The serum concentration of Prazepam can be increased when it is combined with Idelalisib. | Approved |
| Iloperidone | The risk or severity of adverse effects can be increased when Prazepam is combined with Iloperidone. | Approved |
| Imatinib | The metabolism of Prazepam can be decreased when combined with Imatinib. | Approved |
| Imipramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Imipramine. | Approved |
| Indalpine | The risk or severity of adverse effects can be increased when Prazepam is combined with Indalpine. | Investigational, Withdrawn |
| Indinavir | The metabolism of Prazepam can be decreased when combined with Indinavir. | Approved |
| Isavuconazonium | The metabolism of Prazepam can be decreased when combined with Isavuconazonium. | Approved, Investigational |
| Isoflurane | The risk or severity of adverse effects can be increased when Isoflurane is combined with Prazepam. | Approved, Vet Approved |
| Isradipine | The metabolism of Prazepam can be decreased when combined with Isradipine. | Approved |
| Itraconazole | The metabolism of Prazepam can be decreased when combined with Itraconazole. | Approved, Investigational |
| Ivacaftor | The serum concentration of Prazepam can be increased when it is combined with Ivacaftor. | Approved |
| Ketamine | The risk or severity of adverse effects can be increased when Ketamine is combined with Prazepam. | Approved, Vet Approved |
| Ketazolam | The risk or severity of adverse effects can be increased when Ketazolam is combined with Prazepam. | Approved |
| Ketobemidone | The risk or severity of adverse effects can be increased when Prazepam is combined with Ketobemidone. | Approved |
| Ketoconazole | The metabolism of Prazepam can be decreased when combined with Ketoconazole. | Approved, Investigational |
| Lamotrigine | The risk or severity of adverse effects can be increased when Prazepam is combined with Lamotrigine. | Approved, Investigational |
| Levetiracetam | The risk or severity of adverse effects can be increased when Prazepam is combined with Levetiracetam. | Approved, Investigational |
| Levobupivacaine | The risk or severity of adverse effects can be increased when Levobupivacaine is combined with Prazepam. | Approved |
| Levocabastine | The risk or severity of adverse effects can be increased when Prazepam is combined with Levocabastine. | Approved |
| Levocetirizine | The risk or severity of adverse effects can be increased when Prazepam is combined with Levocetirizine. | Approved |
| Levodopa | The risk or severity of adverse effects can be increased when Prazepam is combined with Levodopa. | Approved |
| Levomethadyl Acetate | The risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Prazepam. | Approved |
| Levomilnacipran | The risk or severity of adverse effects can be increased when Prazepam is combined with Levomilnacipran. | Approved |
| Levorphanol | The risk or severity of adverse effects can be increased when Levorphanol is combined with Prazepam. | Approved |
| Lidocaine | The risk or severity of adverse effects can be increased when Lidocaine is combined with Prazepam. | Approved, Vet Approved |
| Lithium | The risk or severity of adverse effects can be increased when Lithium is combined with Prazepam. | Approved |
| Lofentanil | The risk or severity of adverse effects can be increased when Prazepam is combined with Lofentanil. | Illicit |
| Lopinavir | The metabolism of Prazepam can be decreased when combined with Lopinavir. | Approved |
| Loratadine | The risk or severity of adverse effects can be increased when Prazepam is combined with Loratadine. | Approved |
| Lorazepam | The risk or severity of adverse effects can be increased when Lorazepam is combined with Prazepam. | Approved |
| Lovastatin | The metabolism of Prazepam can be decreased when combined with Lovastatin. | Approved, Investigational |
| Loxapine | The risk or severity of adverse effects can be increased when Loxapine is combined with Prazepam. | Approved |
| Luliconazole | The serum concentration of Prazepam can be increased when it is combined with Luliconazole. | Approved |
| Lumacaftor | The metabolism of Prazepam can be increased when combined with Lumacaftor. | Approved |
| Lurasidone | The risk or severity of adverse effects can be increased when Prazepam is combined with Lurasidone. | Approved |
| Magnesium Sulfate | Magnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Vet Approved |
| Maprotiline | The risk or severity of adverse effects can be increased when Prazepam is combined with Maprotiline. | Approved |
| Meclizine | The risk or severity of adverse effects can be increased when Prazepam is combined with Meclizine. | Approved |
| Melatonin | The risk or severity of adverse effects can be increased when Melatonin is combined with Prazepam. | Approved, Nutraceutical, Vet Approved |
| Melperone | The risk or severity of adverse effects can be increased when Prazepam is combined with Melperone. | Approved |
| Mepivacaine | The risk or severity of adverse effects can be increased when Mepivacaine is combined with Prazepam. | Approved, Vet Approved |
| Meprobamate | The risk or severity of adverse effects can be increased when Meprobamate is combined with Prazepam. | Approved, Illicit |
| Mesoridazine | The risk or severity of adverse effects can be increased when Mesoridazine is combined with Prazepam. | Approved |
| Metaxalone | The risk or severity of adverse effects can be increased when Prazepam is combined with Metaxalone. | Approved |
| Methadone | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methadone. | Approved |
| Methadyl Acetate | The risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Prazepam. | Approved, Illicit |
| Methapyrilene | The risk or severity of adverse effects can be increased when Prazepam is combined with Methapyrilene. | Withdrawn |
| Methaqualone | The risk or severity of adverse effects can be increased when Prazepam is combined with Methaqualone. | Illicit, Withdrawn |
| Methocarbamol | The risk or severity of adverse effects can be increased when Prazepam is combined with Methocarbamol. | Approved, Vet Approved |
| Methohexital | The risk or severity of adverse effects can be increased when Methohexital is combined with Prazepam. | Approved |
| Methotrimeprazine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. | Approved |
| Methoxyflurane | The risk or severity of adverse effects can be increased when Methoxyflurane is combined with Prazepam. | Approved, Vet Approved |
| Methsuximide | The risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide. | Approved |
| Methylecgonine | The risk or severity of adverse effects can be increased when Prazepam is combined with ECGONINE METHYL ESTER. | Experimental |
| Methylphenobarbital | The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Prazepam. | Approved |
| Metyrosine | Prazepam may increase the sedative activities of Metyrosine. | Approved |
| Midazolam | The risk or severity of adverse effects can be increased when Midazolam is combined with Prazepam. | Approved, Illicit |
| Mifepristone | The serum concentration of Prazepam can be increased when it is combined with Mifepristone. | Approved, Investigational |
| Milnacipran | The risk or severity of adverse effects can be increased when Prazepam is combined with Milnacipran. | Approved |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Investigational |
| Mirtazapine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. | Approved |
| Mitotane | The serum concentration of Prazepam can be decreased when it is combined with Mitotane. | Approved |
| Modafinil | The serum concentration of Prazepam can be decreased when it is combined with Modafinil. | Approved, Investigational |
| Molindone | The risk or severity of adverse effects can be increased when Prazepam is combined with Molindone. | Approved |
| Morphine | The risk or severity of adverse effects can be increased when Morphine is combined with Prazepam. | Approved, Investigational |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved, Investigational |
| Nafcillin | The serum concentration of Prazepam can be decreased when it is combined with Nafcillin. | Approved |
| Nalbuphine | The risk or severity of adverse effects can be increased when Nalbuphine is combined with Prazepam. | Approved |
| Nefazodone | The metabolism of Prazepam can be decreased when combined with Nefazodone. | Approved, Withdrawn |
| Nelfinavir | The metabolism of Prazepam can be decreased when combined with Nelfinavir. | Approved |
| Netupitant | The serum concentration of Prazepam can be increased when it is combined with Netupitant. | Approved |
| Nevirapine | The metabolism of Prazepam can be increased when combined with Nevirapine. | Approved |
| Nilotinib | The metabolism of Prazepam can be decreased when combined with Nilotinib. | Approved, Investigational |
| Nitrazepam | The risk or severity of adverse effects can be increased when Prazepam is combined with Nitrazepam. | Approved |
| Nitrous oxide | The risk or severity of adverse effects can be increased when Prazepam is combined with Nitrous oxide. | Approved, Vet Approved |
| Norflurane | The risk or severity of adverse effects can be increased when Prazepam is combined with 1,1,1,2 Tetrafluoroethane. | Investigational |
| Normethadone | The risk or severity of adverse effects can be increased when Prazepam is combined with Normethadone. | Approved, Illicit |
| Nortriptyline | The risk or severity of adverse effects can be increased when Prazepam is combined with Nortriptyline. | Approved |
| Olanzapine | The risk or severity of adverse effects can be increased when Olanzapine is combined with Prazepam. | Approved, Investigational |
| Olaparib | The metabolism of Prazepam can be decreased when combined with Olaparib. | Approved |
| Olopatadine | The risk or severity of adverse effects can be increased when Prazepam is combined with Olopatadine. | Approved |
| Ondansetron | The risk or severity of adverse effects can be increased when Ondansetron is combined with Prazepam. | Approved |
| Opium | The risk or severity of adverse effects can be increased when Prazepam is combined with Opium. | Approved, Illicit |
| Orphenadrine | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. | Approved |
| Osanetant | The risk or severity of adverse effects can be increased when Prazepam is combined with Osanetant. | Investigational |
| Osimertinib | The serum concentration of Prazepam can be increased when it is combined with Osimertinib. | Approved |
| Oxazepam | The risk or severity of adverse effects can be increased when Oxazepam is combined with Prazepam. | Approved |
| Oxethazaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Oxetacaine. | Investigational |
| Oxprenolol | The risk or severity of adverse effects can be increased when Oxprenolol is combined with Prazepam. | Approved |
| Oxybuprocaine | The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Prazepam. | Approved |
| Oxycodone | The risk or severity of adverse effects can be increased when Oxycodone is combined with Prazepam. | Approved, Illicit, Investigational |
| Oxymorphone | The risk or severity of adverse effects can be increased when Oxymorphone is combined with Prazepam. | Approved, Investigational, Vet Approved |
| Palbociclib | The serum concentration of Prazepam can be increased when it is combined with Palbociclib. | Approved |
| Paliperidone | The risk or severity of adverse effects can be increased when Paliperidone is combined with Prazepam. | Approved |
| Paraldehyde | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. | Approved |
| Paroxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Paroxetine. | Approved, Investigational |
| Pentazocine | The risk or severity of adverse effects can be increased when Pentazocine is combined with Prazepam. | Approved, Vet Approved |
| Pentobarbital | The metabolism of Prazepam can be increased when combined with Pentobarbital. | Approved, Vet Approved |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved |
| Perazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Perazine. | Investigational |
| Perospirone | The risk or severity of adverse effects can be increased when Prazepam is combined with Perospirone. | Approved |
| Perphenazine | The risk or severity of adverse effects can be increased when Perphenazine is combined with Prazepam. | Approved |
| Pethidine | The risk or severity of adverse effects can be increased when Pethidine is combined with Prazepam. | Approved |
| Phenobarbital | The metabolism of Prazepam can be increased when combined with Phenobarbital. | Approved |
| Phenytoin | The serum concentration of Phenytoin can be increased when it is combined with Prazepam. | Approved, Vet Approved |
| Pimozide | The risk or severity of adverse effects can be increased when Pimozide is combined with Prazepam. | Approved |
| Pipamperone | The risk or severity of adverse effects can be increased when Prazepam is combined with Pipamperone. | Approved |
| Pipotiazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Pipotiazine. | Approved |
| Piritramide | The risk or severity of adverse effects can be increased when Prazepam is combined with Piritramide. | Investigational |
| Pomalidomide | The risk or severity of adverse effects can be increased when Prazepam is combined with Pomalidomide. | Approved |
| Posaconazole | The metabolism of Prazepam can be decreased when combined with Posaconazole. | Approved, Investigational, Vet Approved |
| Pramipexole | Prazepam may increase the sedative activities of Pramipexole. | Approved, Investigational |
| Pramocaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Pramocaine. | Approved |
| Pregabalin | The risk or severity of adverse effects can be increased when Pregabalin is combined with Prazepam. | Approved, Illicit, Investigational |
| Prilocaine | The risk or severity of adverse effects can be increased when Prilocaine is combined with Prazepam. | Approved |
| Primidone | The metabolism of Prazepam can be increased when combined with Primidone. | Approved, Vet Approved |
| Procaine | The risk or severity of adverse effects can be increased when Procaine is combined with Prazepam. | Approved, Investigational, Vet Approved |
| Prochlorperazine | The risk or severity of adverse effects can be increased when Prochlorperazine is combined with Prazepam. | Approved, Vet Approved |
| Promazine | The risk or severity of adverse effects can be increased when Promazine is combined with Prazepam. | Approved, Vet Approved |
| Promethazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Promethazine. | Approved |
| Proparacaine | The risk or severity of adverse effects can be increased when Proparacaine is combined with Prazepam. | Approved, Vet Approved |
| Propofol | The risk or severity of adverse effects can be increased when Propofol is combined with Prazepam. | Approved, Investigational, Vet Approved |
| Propoxycaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Propoxycaine. | Approved |
| Protriptyline | The risk or severity of adverse effects can be increased when Prazepam is combined with Protriptyline. | Approved |
| Quazepam | The risk or severity of adverse effects can be increased when Prazepam is combined with Quazepam. | Approved, Illicit |
| Quetiapine | The risk or severity of adverse effects can be increased when Quetiapine is combined with Prazepam. | Approved |
| Raclopride | The risk or severity of adverse effects can be increased when Prazepam is combined with Raclopride. | Investigational |
| Ramelteon | The risk or severity of adverse effects can be increased when Prazepam is combined with Ramelteon. | Approved, Investigational |
| Ranolazine | The metabolism of Prazepam can be decreased when combined with Ranolazine. | Approved, Investigational |
| Remifentanil | The risk or severity of adverse effects can be increased when Remifentanil is combined with Prazepam. | Approved |
| Remoxipride | The risk or severity of adverse effects can be increased when Remoxipride is combined with Prazepam. | Approved, Withdrawn |
| Reserpine | The risk or severity of adverse effects can be increased when Reserpine is combined with Prazepam. | Approved |
| Rifabutin | The metabolism of Prazepam can be increased when combined with Rifabutin. | Approved |
| Rifampicin | The metabolism of Prazepam can be increased when combined with Rifampicin. | Approved |
| Rifapentine | The metabolism of Prazepam can be increased when combined with Rifapentine. | Approved |
| Risperidone | The risk or severity of adverse effects can be increased when Risperidone is combined with Prazepam. | Approved, Investigational |
| Ritanserin | The risk or severity of adverse effects can be increased when Prazepam is combined with Ritanserin. | Investigational |
| Ritonavir | The metabolism of Prazepam can be decreased when combined with Ritonavir. | Approved, Investigational |
| Ropinirole | Prazepam may increase the sedative activities of Ropinirole. | Approved, Investigational |
| Ropivacaine | The risk or severity of adverse effects can be increased when Ropivacaine is combined with Prazepam. | Approved |
| Rotigotine | Prazepam may increase the sedative activities of Rotigotine. | Approved |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with Prazepam. | Approved |
| Saquinavir | The metabolism of Prazepam can be decreased when combined with Saquinavir. | Approved, Investigational |
| Scopolamine | The risk or severity of adverse effects can be increased when Prazepam is combined with Scopolamine. | Approved |
| Secobarbital | The risk or severity of adverse effects can be increased when Secobarbital is combined with Prazepam. | Approved, Vet Approved |
| Sepranolone | The risk or severity of adverse effects can be increased when Prazepam is combined with Uc1010. | Investigational |
| Sertindole | The risk or severity of adverse effects can be increased when Prazepam is combined with Sertindole. | Approved, Withdrawn |
| Sertraline | The risk or severity of adverse effects can be increased when Prazepam is combined with Sertraline. | Approved |
| Sevoflurane | The risk or severity of adverse effects can be increased when Sevoflurane is combined with Prazepam. | Approved, Vet Approved |
| Sildenafil | The metabolism of Prazepam can be decreased when combined with Sildenafil. | Approved, Investigational |
| Siltuximab | The serum concentration of Prazepam can be decreased when it is combined with Siltuximab. | Approved |
| Simeprevir | The serum concentration of Prazepam can be increased when it is combined with Simeprevir. | Approved |
| Sodium oxybate | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. | Approved |
| St. John's Wort | The serum concentration of Prazepam can be decreased when it is combined with St. John's Wort. | Nutraceutical |
| Stiripentol | The serum concentration of Prazepam can be increased when it is combined with Stiripentol. | Approved |
| Sufentanil | The risk or severity of adverse effects can be increased when Sufentanil is combined with Prazepam. | Approved, Investigational |
| Sulfisoxazole | The metabolism of Prazepam can be decreased when combined with Sulfisoxazole. | Approved, Vet Approved |
| Sulpiride | The risk or severity of adverse effects can be increased when Sulpiride is combined with Prazepam. | Approved |
| Suvorexant | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. | Approved |
| Tandospirone | The risk or severity of adverse effects can be increased when Prazepam is combined with Tandospirone. | Investigational |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Prazepam. | Approved |
| Tasimelteon | The risk or severity of adverse effects can be increased when Prazepam is combined with Tasimelteon. | Approved |
| Teduglutide | The serum concentration of Prazepam can be increased when it is combined with Teduglutide. | Approved |
| Telaprevir | The metabolism of Prazepam can be decreased when combined with Telaprevir. | Withdrawn |
| Telithromycin | The metabolism of Prazepam can be decreased when combined with Telithromycin. | Approved |
| Temazepam | The risk or severity of adverse effects can be increased when Temazepam is combined with Prazepam. | Approved |
| Tetrabenazine | The risk or severity of adverse effects can be increased when Prazepam is combined with Tetrabenazine. | Approved |
| Tetracaine | The risk or severity of adverse effects can be increased when Prazepam is combined with Tetracaine. | Approved, Vet Approved |
| Tetrodotoxin | The risk or severity of adverse effects can be increased when Prazepam is combined with Tetrodotoxin. | Investigational |
| Thalidomide | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. | Approved, Investigational, Withdrawn |
| Theophylline | The therapeutic efficacy of Prazepam can be decreased when used in combination with Theophylline. | Approved |
| Thiamylal | The risk or severity of adverse effects can be increased when Thiamylal is combined with Prazepam. | Approved, Vet Approved |
| Thiopental | The risk or severity of adverse effects can be increased when Thiopental is combined with Prazepam. | Approved, Vet Approved |
| Thioridazine | The risk or severity of adverse effects can be increased when Thioridazine is combined with Prazepam. | Withdrawn |
| Thiothixene | The risk or severity of adverse effects can be increased when Prazepam is combined with Thiothixene. | Approved |
| Tiagabine | The risk or severity of adverse effects can be increased when Prazepam is combined with Tiagabine. | Approved |
| Tiapride | The risk or severity of adverse effects can be increased when Prazepam is combined with Tiapride. | Approved, Investigational |
| Ticlopidine | The metabolism of Prazepam can be decreased when combined with Ticlopidine. | Approved |
| Tizanidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Tizanidine. | Approved |
| Tocilizumab | The serum concentration of Prazepam can be decreased when it is combined with Tocilizumab. | Approved |
| Tolcapone | The risk or severity of adverse effects can be increased when Prazepam is combined with Tolcapone. | Approved, Withdrawn |
| Topiramate | The risk or severity of adverse effects can be increased when Prazepam is combined with Topiramate. | Approved |
| Tramadol | The risk or severity of adverse effects can be increased when Tramadol is combined with Prazepam. | Approved, Investigational |
| Trans-2-Phenylcyclopropylamine | The risk or severity of adverse effects can be increased when Prazepam is combined with Trans-2-Phenylcyclopropylamine. | Experimental |
| Tranylcypromine | The risk or severity of adverse effects can be increased when Tranylcypromine is combined with Prazepam. | Approved |
| Trazodone | The risk or severity of adverse effects can be increased when Trazodone is combined with Prazepam. | Approved, Investigational |
| Triazolam | The risk or severity of adverse effects can be increased when Triazolam is combined with Prazepam. | Approved |
| Trifluoperazine | The risk or severity of adverse effects can be increased when Trifluoperazine is combined with Prazepam. | Approved |
| Triflupromazine | The risk or severity of adverse effects can be increased when Triflupromazine is combined with Prazepam. | Approved, Vet Approved |
| Trimipramine | The risk or severity of adverse effects can be increased when Prazepam is combined with Trimipramine. | Approved |
| Triprolidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Triprolidine. | Approved |
| Valproic Acid | The risk or severity of adverse effects can be increased when Valproic Acid is combined with Prazepam. | Approved, Investigational |
| Venlafaxine | The metabolism of Prazepam can be decreased when combined with Venlafaxine. | Approved |
| Verapamil | The metabolism of Prazepam can be decreased when combined with Verapamil. | Approved |
| Vigabatrin | The risk or severity of adverse effects can be increased when Prazepam is combined with Vigabatrin. | Approved |
| Voriconazole | The metabolism of Prazepam can be decreased when combined with Voriconazole. | Approved, Investigational |
| Vortioxetine | The risk or severity of adverse effects can be increased when Prazepam is combined with Vortioxetine. | Approved |
| Yohimbine | The therapeutic efficacy of Prazepam can be decreased when used in combination with Yohimbine. | Approved, Vet Approved |
| Zaleplon | The risk or severity of adverse effects can be increased when Zaleplon is combined with Prazepam. | Approved, Illicit, Investigational |
| Ziconotide | The risk or severity of adverse effects can be increased when Prazepam is combined with Ziconotide. | Approved |
| Zimelidine | The risk or severity of adverse effects can be increased when Prazepam is combined with Zimelidine. | Withdrawn |
| Ziprasidone | The metabolism of Prazepam can be decreased when combined with Ziprasidone. | Approved |
| Zolpidem | Prazepam may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. | Approved |
| Zonisamide | The risk or severity of adverse effects can be increased when Prazepam is combined with Zonisamide. | Approved, Investigational |
| Zopiclone | The risk or severity of adverse effects can be increased when Zopiclone is combined with Prazepam. | Approved |
| Zotepine | The risk or severity of adverse effects can be increased when Prazepam is combined with Zotepine. | Approved |
| Zuclopenthixol | The risk or severity of adverse effects can be increased when Prazepam is combined with Zuclopenthixol. | Approved, Investigational |
